NCCN recognizes Oncotype DX test as the only multigene test to predict chemotherapy benefit in node-positive early-stage breast cancer

We catch up with Kimryn Rathmell on her first day as CEO at OSUCCC – James

At the end of her first day on the job as CEO of The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, W. Kimryn Rathmell reflected on her decision to take the CEO job at the third largest cancer hospital in the United States.

May 30, 2025

By Paul Goldberg

Pfizer seeks to improve breast cancer outcomes in Sub-Saharan Africa
With help from Conquer Cancer’s EveryGrant and ASCO’s Sub-Saharan Africa Regional Council, Pfizer awards grants to seven countries

Pfizer External Research & Grants’ “Improving Breast Cancer Quality of Care via Meaningful Capacity Building in Sub-Saharan Africa,” powered by EveryGrant, has announced grants totaling more than $900,000 for addressing inequities and improving the quality of breast cancer care in Sub-Saharan Africa.

May 30, 2025

By Claire Marie Porter

Clinical Trials & Tribulations

The other side of the patient portal: Reflections from a cancer center leader

It started innocuously enough. I looked in the mirror and noticed a pigmented area on my scalp just into the hairline. Like many patients, thoughts started running through my head: “Maybe it’s nothing.” Looking at my Outlook calendar, it was packed morning-to-night with meetings, patients, and travel, so I decided I would get that spot checked out the minute I had “time.”

May 30, 2025

By Ruben A. Mesa

Clinical Trials & Tribulations

Surviving cancer is often not a patient’s most challenging battle

With advances in treatment and screening for earlier detection, oncologists have improved cancer survival rates dramatically. That is excellent news, but the surging number of survivors means it is increasingly important for providers to focus more diligently on what patients need to thrive after treatment.

May 30, 2025

By Boris C. Pasche

Podcast

In The Headlines: Back to “business as usual” at FDA?

The Oncologic Drugs Advisory Committee held its first session since President Trump’s inauguration, with a two-day, back-to-back marathon meeting, signaling a return to business at FDA after significant upheaval at the agency.

May 28, 2025

Vol.51 No.20

Regulatory News

ODAC marathon: Committee charges through a pileup of clinical questions in a two-day, four-application session

In two back-to-back, all-day meetings, the FDA Oncologic Drugs Advisory Committee considered four thorny applications that the agency appeared to have been saving up as a result of the pause in activity that followed President Trump’s return to office.

May 23, 2025

Vol.51 No.20

By Jacquelyn Cobb

NCCN recognizes Oncotype DX test as the only multigene test to predict chemotherapy benefit in node-positive early-stage breast cancer

YOU MAY BE INTERESTED IN

We catch up with Kimryn Rathmell on her first day as CEO at OSUCCC – James

Pfizer seeks to improve breast cancer outcomes in Sub-Saharan Africa
With help from Conquer Cancer’s EveryGrant and ASCO’s Sub-Saharan Africa Regional Council, Pfizer awards grants to seven countries

The other side of the patient portal: Reflections from a cancer center leader

Surviving cancer is often not a patient’s most challenging battle

In The Headlines: Back to “business as usual” at FDA?

ODAC marathon: Committee charges through a pileup of clinical questions in a two-day, four-application session

Renew today!

Subscriber content

Never miss an issue!

Login

NCCN recognizes Oncotype DX test as the only multigene test to predict chemotherapy benefit in node-positive early-stage breast cancer

YOU MAY BE INTERESTED IN

We catch up with Kimryn Rathmell on her first day as CEO at OSUCCC – James

Pfizer seeks to improve breast cancer outcomes in Sub-Saharan AfricaWith help from Conquer Cancer’s EveryGrant and ASCO’s Sub-Saharan Africa Regional Council, Pfizer awards grants to seven countries

The other side of the patient portal: Reflections from a cancer center leader

Surviving cancer is often not a patient’s most challenging battle

In The Headlines: Back to “business as usual” at FDA?

ODAC marathon: Committee charges through a pileup of clinical questions in a two-day, four-application session

Never miss an issue!

Login

Pfizer seeks to improve breast cancer outcomes in Sub-Saharan Africa
With help from Conquer Cancer’s EveryGrant and ASCO’s Sub-Saharan Africa Regional Council, Pfizer awards grants to seven countries